Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed EBITDA Margin for 5 consecutive years, with 65.61% as the latest value for Q2 2024.

  • Quarterly EBITDA Margin rose 316698.0% to 65.61% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 3.74% through Mar 2025, up 437443.0% year-over-year, with the annual reading at 11.82% for FY2024, 343466.0% up from the prior year.
  • EBITDA Margin for Q2 2024 was 65.61% at Fulcrum Therapeutics, up from 3213.78% in the prior quarter.
  • The five-year high for EBITDA Margin was 65.61% in Q2 2024, with the low at 9471.19% in Q1 2023.
  • Average EBITDA Margin over 5 years is 2041.4%, with a median of 1028.79% recorded in 2020.
  • The sharpest move saw EBITDA Margin plummeted -844414bps in 2023, then skyrocketed 316698bps in 2024.
  • Over 5 years, EBITDA Margin stood at 420.19% in 2020, then dropped by -12bps to 470.42% in 2021, then crashed by -768bps to 4083.65% in 2022, then grew by 21bps to 3213.78% in 2023, then surged by 102bps to 65.61% in 2024.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 65.61%, 3213.78%, and 3615.28% for Q2 2024, Q4 2023, and Q3 2023 respectively.